Pasireotide
- Generic Name
- Pasireotide
- Brand Names
- Signifor
- Drug Type
- Small Molecule
- Chemical Formula
- C58H66N10O9
- CAS Number
- 396091-73-9
- Unique Ingredient Identifier
- 98H1T17066
- Background
Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.
- Indication
For the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.
- Associated Conditions
- Acromegaly, Cushing's Disease
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 123
- Registration Number
- NCT02354508
- Locations
- 🇬🇧
Novartis Investigative Site, Plymouth, United Kingdom
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- RECORDATI GROUP
- Target Recruit Count
- 152
- Registration Number
- NCT02310269
- Locations
- 🇨🇦
Centre de recherche du CHUM CRCHUM, Montreal, Quebec, Canada
🇨🇦CHUS - Hopital Fleurimont, Sherbrooke, Quebec, Canada
🇨🇦CHUL Centre de recherche du CHU, Quebec, Canada
Pasireotide in Prevention of GI Toxicity
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Anthony Sung, MD
- Target Recruit Count
- 37
- Registration Number
- NCT02215070
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
- Conditions
- Cushing's DiseaseAcromegaly
- Interventions
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 249
- Registration Number
- NCT02060383
- Locations
- 🇺🇸
LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219, Torrance, California, United States
🇺🇸Diabetes and Endocrine Associates La Mesa Location, Multiple Locations, California, United States
🇺🇸East Coast Institute for Research East Coast Inst. for Res(ECIR), Jacksonville, Florida, United States
Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Hepatic Cysts
- Conditions
- Symptomatic Dominant Liver Cyst
- Interventions
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 34
- Registration Number
- NCT02048319
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Center; Department of Gastroenterology & Hepatology, Nijmegen, Netherlands
Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
- Conditions
- Primary Inoperable ThymomaLocal Recurrent Thymoma
- Interventions
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Prof. Dr. Berthold Schalke
- Target Recruit Count
- 16
- Registration Number
- NCT02021942
- Locations
- 🇩🇪
Klinik und Poliklinik für Neurologie der Universität Regensburg, Regensburg, Bavaria, Germany
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
- Conditions
- Acromegaly
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01995734
- Locations
- 🇺🇸
The Johns Hopkins University School of Medicine Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Harbor-UCLA Medical Center Center for Men's Health, Torrance, California, United States
🇺🇸Sinai Hospital of Baltimore Sinai Hospital, Baltimore, Baltimore, Maryland, United States
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
- Conditions
- Cushings Disease
- Interventions
- First Posted Date
- 2013-08-02
- Last Posted Date
- 2020-09-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 68
- Registration Number
- NCT01915303
- Locations
- 🇺🇸
Oregon Health and Science University SOM230B2411, Portland, Oregon, United States
🇹🇷Novartis Investigative Site, Pendik / Istanbul, Turkey
🇺🇸University of Alabama at Birmingham The Kirklin Clinic, Birmingham, Alabama, United States
Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 9
- Registration Number
- NCT01895296
- Locations
- 🇧🇪
University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
- Conditions
- AcromegalyPituitary TumorsEctopic ACTH Secreting (EAS) TumorsMelanoma Negative for bRAFCushing's DiseaseNeuroendocrine TumorsProstate CancerMelanoma Negative for nRASDumping Syndrome
- Interventions
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- RECORDATI GROUP
- Target Recruit Count
- 337
- Registration Number
- NCT01794793
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States
🇮🇹Milano Investigative Site, Milano, MI, Italy
🇺🇸Ximed Research SC - SOM230B2412, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.